National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nintedanib (Ofev®)

Nintedanib (Ofev®) indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Rapid Review

Commenced Completed Outcome
30/01/2015 18/02/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
10/09/2015  22/02/2016 Reimbursement Not Recommended at the Submitted Price


June 2017

The HSE has approved reimbursement following confidential price negotiations.